The development of lipid-lowering therapies has been inspired by human mutants with low blood lipids and reduced risk of cardiovascular disease. These therapies aim to mimic the effects of these mutations, although they offer smaller benefits. Advances in therapy have shifted towards small interfering RNA to target specific genes like ANGPLT3. A recent clinical trial of an ANGPLT3 inhibitor, zodasiran, showed promising results in reducing various atherogenic lipoproteins with less frequent dosing than conventional treatments. Specifically targeting the gene ANGPLT3, zodasiran demonstrated significant reductions in triglycerides, LDL cholesterol, non-HDL cholesterol, and remnant cholesterol in individuals with mixed hyperlipidemia. These results suggest the potential for reducing the risk of atherosclerotic cardiovascular disease.
A recent phase 2b trial, ARCHES-2, showed reductions in lipid levels in participants receiving zodasiran alongside standard of care medications. The therapy decreased triglycerides by 54 to 74 percent, LDL cholesterol by up to 20 percent, non-HDL cholesterol by up to 36 percent, and remnant cholesterol by 73 to 82 percent. Researchers believe that the reduction in remnant cholesterol could lead to a 20 percent decrease in recurrent major cardiac events. This advancement in lipid-lowering therapy marks a significant step in combating cardiovascular disease.
